Remus Pharmaceuticals (NSE:REMUS) Shares Outstanding (EOP): 9 Mil (As of Mar. 2026)


NSE:REMUS Remus Pharmaceuticals Ltd NSE:REMUS
54 GF Score
Price ₹767.40
GF Value ₹2,071.36
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Remus Pharmaceuticals Shares Outstanding (EOP)?

Remus Pharmaceuticals NSE:REMUS +2.86% 54 Shares Outstanding (EOP) is 9 Mil as of Mar. 2026. GuruFocus rates NSE:REMUS with a GF Score™ of 54/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Remus Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 9 Mil.

Remus Pharmaceuticals's quarterly shares outstanding declined from Sep. 2025 (12 Mil) to Mar. 2026 (9 Mil). It means Remus Pharmaceuticals bought back shares from Sep. 2025 to Mar. 2026 .

Remus Pharmaceuticals's annual shares outstanding declined from Mar. 2025 (12 Mil) to Mar. 2026 (9 Mil). It means Remus Pharmaceuticals bought back shares from Mar. 2025 to Mar. 2026 .


Remus Pharmaceuticals  (NSE:REMUS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Remus Pharmaceuticals Shares Outstanding (EOP) Related Terms


Remus Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Remus Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remus Pharmaceuticals Shares Outstanding (EOP) Chart

Remus Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
Get a 7-Day Free Trial 11.78 11.78 11.78 11.78 9.44

Remus Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.78 11.78 11.78 11.78 9.44

NSE:REMUS vs MCK, CAH, COR: Shares Outstanding (EOP) Comparison

For the Medical Distribution subindustry, Remus Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remus Pharmaceuticals Shares Outstanding (EOP) vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's Shares Outstanding (EOP) falls into.


NSE:REMUS
54GF Score
Remus Pharmaceuticals Ltd NSE:REMUS
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remus Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 9 Mil mean?
Remus Pharmaceuticals (NSE:REMUS) has a Shares Outstanding (EOP) of 9 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Shares Outstanding (EOP) too high?
Remus Pharmaceuticals' current Shares Outstanding (EOP) is 9 Mil. Overall, Remus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Shares Outstanding (EOP) compare to MCK and CAH?
Remus Pharmaceuticals' Shares Outstanding (EOP) of 9 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Distribution company?
A good Shares Outstanding (EOP) depends on the Medical Distribution industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Remus Pharmaceuticals and its competitors. Remus Pharmaceuticals's current Shares Outstanding (EOP) is 9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹767.40 — trading 63% below its estimated fair value. The current Shares Outstanding (EOP) is 9 Mil. Remus Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Shares Outstanding (EOP) is 9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?

Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued. The current stock price of ₹767.40 is trading 63% below its estimated GF Value™ of ₹2,071.36. GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:REMUS:

  • Shares Outstanding (EOP): 9 Mil
  • GF Value™: ₹2,071.36 vs. price of ₹767.40 (63% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Remus Pharmaceuticals Business Description

Address Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
54GF Score

Get the complete analysis for NSE:REMUS

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹767.40
Price
₹2,071.36
GF Value